Carbamazepine is an early anticonvulsant still used today in the treatment of several forms of epilepsy. An active metabolite in the human body contributes to its pharmacological effect. Carbamazepine metabolism has high inter-individual variability, such that it is relatively difficult to establish a direct link between dose and concentration, or between concentration and pharmacological effect.
Introduction
Epilepsy is a common neurological disorder. The probability of an individual developing the disorder during a lifetime is between 3% and 5%. Newborn, children, and the elderly have the highest risk of developing epilepsy. An epileptic seizure is defined as a paroxysmal discharge of cerebral neurons, followed by obvious clinical phenomena: motor, sensory, and autonomic, with impairment or complete loss of consciousness. Epilepsy is defined as a condition Also the social consequences should not be overlooked, especially in the case of diagnostic errors (for example: the loss of the driver's license) (5) . On the other hand, waiting too long to treat must also be avoided. There are insufficient data to support the contention that seizures affect brain tissue and diminish cognitive capacity, but it is known that status epilepticus is a contributing factor to brain injury and death (1).
However, the most compelling reasons to start antiepileptic treatment are the risk of personal injury, the risk of causing harm to others, and the psychosocial consequences of untreated epilepsy: low self-esteem, anxiety, and domestic and employment difficulties (1) .
The choice of the drug used for treatment is determined mainly by its efficacy against the seizures and the potential adverse effects. Monotherapy is preferred. of patients taking carbamazepine experience cutaneous adverse drug reactions. Carriers of specific HLA variants are known to be susceptible to carbamazepine-induced hypersensitivity reactions. Therefore, HLA testing of patients can identify those at-risk individuals so that an alternative drug can be used (8) .
Therapy and posology
In epilepsy, carbamazepine is administered in doses of 0.8-1.2 g/day for 2-3 times a day for an adult and 0.1- 
Bioanalytical methods for determination of carbamazepine and metabolite
In Table 1 UV spectrophotometric methods have been reported for carbamazepine in pharmaceutical formulations (40, 41) . These methods are not applicable to biological samples because they fall short with regards to specificity: interference from sample matrix or co-medication is highly possible and differentiation between carbamazepine and metabolites is not possible.
Immunoassays have also been reported for determination in plasma (31) . In one case immunoassays were used to generate mathematical equations for determination of carbamazepine and its metabolite in plasma (19) . Tables 2 to 5 Results for accuracy are presented as minimum and maximum values obtained for inter-day and intra-day, where applicable. 
